Work

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIb Clinical Trial Evaluating the Efficacy and Safety of Mecasin (KCHO-1) in Adults with Amyotrophic Lateral Sclerosis

Year: 2026
Type: article
Abstract: Background/Objectives: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive muscle weakness and paralysis, with respiratory failure being the leading cause of death. Mecasin (KCHO-1), a standardized botanical extract, has demonstrated neuroprotective and anti-neuroinflammatory effects in preclinical studies. A 12-week phase IIa trial suggested a potential benefit in slowing functional decline. This phase IIb trial evaluated the efficacy and safety of Mecasin over 24 weeks, including respiratory-related outcomes. Methods: In this multicenter, randomized, double-blind, placebo-controlled trial, 50 patients were randomized to receive Mecasin (2.4 g/day) or placebo for 24 weeks, with both groups receiving riluzole (100 mg/day). Forty-three patients were included in the efficacy analysis. The primary endpoint was change in the Korean version of the ALS Functional Rating Scale-Revised (K-ALSFRS-R) total score. Respiratory-related assessments included orthopnea, FEV1/FVC, and end-tidal CO2, alongside safety evaluations. Results: At week 24, K-ALSFRS-R changes were −3.65 and −3.74 points in the Mecasin and placebo groups, respectively, with no significant between-group difference (estimated difference, 0.27; 90% CI, −1.80 to 2.33; p = 0.4146). Significant between-group differences were observed in FEV1/FVC (7.69 percentage points; p = 0.0036) and end-tidal CO2 (−3.92 mmHg; p = 0.0076). Linear mixed-effects models showed significant group-by-visit interactions for orthopnea (p = 0.0212) and FEV1/FVC (p = 0.0228). Adverse-event frequencies were comparable. Conclusions: Although Mecasin did not show a significant effect on the primary outcome (K-ALSFRS-R total score), the observed differences in respiratory-related outcomes provide a clinical rationale for further investigation in larger trials focusing on respiratory function.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,137
OpenAlex ID: W7236830554
FWCI:
Cites: 40
Cited by:
Related to: 10